The Situation

Spondyloarthritis (SpA) has common genetic, clinical, and radiological features; characterised by inflammatory back pain, fatigue and joint swelling as well as comorbidities such as inflammatory bowel disease, psoriasis and osteoporotic fractures which pose a significant burden to the patient.1,2

Early diagnosis is important to improve outcomes; however, diagnosis is often delayed from symptom onset by as much as 6–8 years.3

CPD Certified. CPD Logo.

 

Treatment strategies and modalities in spondyloarthritis have tremendously improved in recent times. With the discovery of new molecular mechanisms, a new series of targets have emerged, opening up the horizon for strategies in achieving disease remission early on and in a stratified manner. International societies have been regularly approving and updating guidelines, and so the disease treatment landscape has evolved rapidly.4

The Solution

The RESPOND interactive education programme is a series of CPD accredited modules, developed in association with five experts in SpA; Professor Karl Gaffney, Dr Deepak Jadon, Professor Dennis McGonagle, Dr Laura Savage and Dr Raj Sengupta, designed to review and update healthcare professionals on the evolving management and future trends of patients with spondyloarthritis and psoriasis.

Key programme objectives:

  • How can rheumatologists best use the resources available to them to reduce the time to diagnosis for spondyloarthritis?
  • Practical use of guidelines and recommendations for the pharmacological (and non-pharmacological) management of AS
  • Showcase a best practice approach for working as an MDT with nurses, primary care and allied specialties

References

  1. Dean LE, et al. Rheumatology (Oxford) 2014;53(4):650–657.
  2. Salaffi F, et al. Health Qual Life Outcomes 2009;7:25.
  3. Almodovar R, et al. Clin Exp Rheumatol 2011;29(5):822–827.
  4. Subramanian R and Prasad S. APIK Journal of Internal Medicine 2020; 8(3):107.
Rate this content: 
No votes yet
UK | February 2022 | 176577
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]